<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="spr-def" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">spr-def</book-part-id>
      <title-group>
        <title>Sepiapterin Reductase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonyms: Dopa-Responsive Hypersomnia, SPR Deficiency, DYT-SPR</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Friedman</surname>
            <given-names>Jennifer</given-names>
          </name>
          <degrees>MD</degrees>
          <email>jrfriedman@rchsd.org</email>
          <aff>Clinical Professor, Neurosciences and Pediatrics<break/>University of California San Diego/Rady Children&#x02019;s Hospital San Diego<break/>San Diego, California</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2015-07-01" date-type="created">
          <day>1</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="siod" document-type="chapter">Schimke Immunoosseous Dysplasia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="short" document-type="chapter">SHORT Syndrome</related-object>
      <abstract id="spr-def.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The phenotypic spectrum of sepiapterin reductase deficiency (SRD), which ranges from significant motor and cognitive deficits to only minimal findings, has not been completely elucidated. Clinical features in the majority of affected individuals include motor and speech delay, axial hypotonia, dystonia, weakness, and oculogyric crises; symptoms show diurnal fluctuation and sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, and drowsiness). Most affected individuals have nonspecific features in infancy including developmental delays and axial hypotonia; other features develop over time.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of sepiapterin reductase deficiency is established in a proband by detection of biallelic pathogenic variants in <italic toggle="yes">SPR</italic> on molecular genetic testing or characteristic abnormalities of CSF neurotransmitters and pterins.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> L-dopa in combination with carbidopa (or another peripheral decarboxylase inhibitor) is the main therapy used to correct CNS dopamine deficiency; 5-hydroxytryptophan (5-HTP), also in combination with carbidopa, has shown additional clinical benefit in some. When L-dopa/5HTP/carbidopa are not tolerated or sufficiently effective some individuals may benefit from use of other agents such as monoamine oxidase inhibitors, serotonin reuptake inhibitors, melatonin, dopamine agonists, anticholinergics, and methylphenidate. These medications most consistently correct motor abnormalities; however, in some individuals cognitive manifestations remain more refractory.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Physical, occupational, and speech therapy may improve or maintain motor function.</p>
          <p><italic toggle="yes">Surveillance:</italic> Data are insufficient to determine how frequently CSF levels of dopamine and serotonin metabolites should be evaluated and whether these levels should be used to adjust medication doses.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Although adverse events with specific agents have not been reported in persons with SRD, the following should be avoided on a theoretical basis: sulfa drugs, methotrexate, nitrous oxide, neuroleptics, and other dopamine antagonists (e.g., metoclopramide).</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Although no data on outcomes are available, it is appropriate to use molecular genetic testing for the <italic toggle="yes">SPR</italic> pathogenic variants identified in the proband and/or analysis of CSF neurotransmitter metabolites and pterins to clarify the genetic status of apparently asymptomatic older and younger sibs of an affected individual in order to identify as soon as possible those who would benefit from early initiation of treatment to correct CNS dopamine and serotonin deficiency.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>SRD is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">SPR</italic> pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="spr-def.Diagnosis">
        <title>Diagnosis</title>
        <p>No formal diagnostic criteria for sepiapterin reductase deficiency (SRD) have been published. A diagnostic algorithm is presented in a recent review [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>].</p>
        <sec id="spr-def.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Sepiapterin reductase deficiency (SRD) should be suspected in individuals with characteristic clinical findings. The phenotypic spectrum is broad and suggestive signs are often nonspecific.</p>
          <p>Core clinical features present in more than 65% of affected individuals:</p>
          <list list-type="bullet">
            <list-item>
              <p>Motor and speech delay</p>
            </list-item>
            <list-item>
              <p>Axial hypotonia</p>
            </list-item>
            <list-item>
              <p>Dystonia</p>
            </list-item>
            <list-item>
              <p>Weakness</p>
            </list-item>
            <list-item>
              <p>Oculogyric crises</p>
            </list-item>
            <list-item>
              <p>Diurnal fluctuation and symptom improvement with sleep</p>
            </list-item>
          </list>
          <p>Other common features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intellectual disability</p>
            </list-item>
            <list-item>
              <p>Limb hypertonia and hyperreflexia</p>
            </list-item>
            <list-item>
              <p>Parkinsonian signs (tremor, bradykinesia, masked facies, rigidity)</p>
            </list-item>
            <list-item>
              <p>Psychiatric and/or behavioral abnormalities</p>
            </list-item>
            <list-item>
              <p>Sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, drowsiness)</p>
            </list-item>
            <list-item>
              <p>Autonomic dysfunction (excessive sweating, ptosis, nasal congestion, temperature instability)</p>
            </list-item>
          </list>
          <p>Individuals with any of the following three broad sets of findings should be considered to possibly have SRD [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Developmental delays with axial hypotonia</p>
            </list-item>
            <list-item>
              <p>Unexplained &#x0201c;cerebral palsy,&#x0201d; especially if dystonia is present</p>
            </list-item>
            <list-item>
              <p>An L-dopa responsive motor disorder that may include dystonia. L-dopa responsiveness is evaluated in the following manner: L-dopa (in combination with 10%-25% carbidopa) may be introduced at 1 mg/kg/day and advanced slowly by 1mg/kg/day over days/weeks monitoring for symptomatic improvement and side effects as the dose is raised. Although data are insufficient to provide precise dosing guidelines, benefit is most often achieved at low dose and is dramatic and rapid (hours to days). Because the response may be delayed or require a high dose (&#x02265;10 mg/kg/d) (as has been observed in <related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">cyclohydrolase 1-deficient dopa-responsive dystonia</related-object> [DYT-GCH1]), the dose should be increased and maintained for two to four weeks &#x02013; barring side effects &#x02013; to fully assess efficacy of L-dopa [Author, personal observation].</p>
            </list-item>
          </list>
          <p>Note: Given the broad range of neurologic manifestations (from asymptomatic to severe global developmental delay) and dramatic response to L-dopa, clinicians should maintain a high index of suspicion for SRD or other monoamine neurotransmitter disorders (see <xref ref-type="sec" rid="spr-def.Differential_Diagnosis">Differential Diagnosis</xref>) in individuals with unexplained neurologic dysfunction.</p>
        </sec>
        <sec id="spr-def.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of sepiapterin reductase deficiency is established in a proband by detection of biallelic pathogenic variants in <italic toggle="yes">SPR</italic> on molecular genetic testing (see <xref ref-type="table" rid="spr-def.T.summary_of_molecular_genetic_t">Table 1</xref>) or characteristic abnormalities of CSF neurotransmitters and pterins.</p>
          <p>Note: (1) While analysis of either sepiapterin reductase enzyme activity in fibroblasts or pterin levels in cytokine stimulated fibroblasts could be considered [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</xref>], neither test is widely available or commonly used. (2) A phenylalanine load test [<xref ref-type="bibr" rid="spr-def.REF.hyland.1997.1290">Hyland et al 1997</xref>], which is not commonly used, could be considered when molecular testing and analysis of CSF neurotransmitters are not available. While an abnormal phenylalanine load is suggestive, it is not diagnostic of SRD, as abnormal results are observed in other BH<sub>4</sub> deficiencies (including <related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">DYT-GCH1</related-object>).</p>
          <p><bold>Molecular genetic testing</bold> approaches may include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis is performed first, followed by consideration of gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found in an individual with characteristic clinical findings and/or abnormalities of CSF metabolites. Note: To date no <italic toggle="yes">SPR</italic> deletions or duplications requiring gene-targeted deletion/duplication analysis have been reported.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">SPR</italic> and other genes of interest (see <xref ref-type="sec" rid="spr-def.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="spr-def.T.summary_of_molecular_genetic_t" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Sepiapterin Reductase Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">SPR</italic>
                  </td>
                  <td headers="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">All sequence variants reported to date&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_spr-def.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="spr-def.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="spr-def" object-id="spr-def.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="spr-def.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="spr-def.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="spr-def.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="spr-def.TF.1.4">
                <label>4. </label>
                <p>A total of approximately 50 probands have been reported to date [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>, <xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>, <xref ref-type="bibr" rid="spr-def.REF.neville.2005.2291">Neville et al 2005</xref>, <xref ref-type="bibr" rid="spr-def.REF.abeling.2006.116">Abeling et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.echenne.2006.308">Echenne et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2006.2032">Friedman et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.verbeek.2008.403">Verbeek et al 2008</xref>, <xref ref-type="bibr" rid="spr-def.REF.clot.2009.1753">Clot et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.kusmierska.2009.s5">Kusmierska et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.leusemenescu.2010.307">Leu-Semenescu et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.mazzuca.2010">Mazzuca et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.wali.2010.954">Wali et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.arrabal.2011.183">Arrabal et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.dill.2012.e29">Dill et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.thibert.2012.79">Thibert et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>, <xref ref-type="bibr" rid="spr-def.REF.koht.2014.7">Koht et al 2014</xref>].</p>
              </fn>
              <fn id="spr-def.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="spr-def.TF.1.6">
                <label>6. </label>
                <p>A single report of deletion involving <italic toggle="yes">SPR</italic> is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar/variation/60181/">listed in ClinVar</ext-link>. In addition to <italic toggle="yes">SPR</italic>, this deletion involves <italic toggle="yes">EMX1</italic> and <italic toggle="yes">SXN5</italic>. No clinical details are provided and thus no conclusions can be drawn regarding the impact of deletion of <italic toggle="yes">SPR</italic>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Characteristic CSF abnormalities of neurotransmitters and pterins</bold> include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Decreased levels of homovanillic acid (HVA) and 5-hyroxyindolacetic acid (5-HIAA);</p>
            </list-item>
            <list-item>
              <p>Normal to slightly increased levels of neopterin;</p>
            </list-item>
            <list-item>
              <p>Increased levels of total biopterin, dihydrobiopterin (BH2), and sepiapterin [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>].Note: (1) CSF should be collected using standardized protocols and analyzed by a laboratory with appropriate age-related reference ranges [<xref ref-type="bibr" rid="spr-def.REF.hyland.1993.10">Hyland et al 1993</xref>, <xref ref-type="bibr" rid="spr-def.REF.br_utigam.2002.287">Br&#x000e4;utigam et al 2002</xref>]. (2) Normal values vary by lab and by age.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="spr-def.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="spr-def.Clinical_Description">
          <title>Clinical Description</title>
          <p>The phenotypic spectrum of sepiapterin reductase deficiency (SRD) has not been completely elucidated due to the small number of affected individuals reported to date, lack of systematic diagnostic evaluation and long-term follow up, and the absence of data on the prevalence and natural history of findings in untreated individuals. Of particular note, severity varies: some individuals manifest significant motor and cognitive deficits and others only minimal findings. Those with minimal findings may present at an older age or be identified because of the diagnosis of SRD in a sib [<xref ref-type="bibr" rid="spr-def.REF.arrabal.2011.183">Arrabal et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>].</p>
          <p>Clinical features in 38 individuals with SRD are summarized by <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al [2012]</xref>. A few affected individuals not included in this review and described elsewhere have additional features [<xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>, <xref ref-type="bibr" rid="spr-def.REF.clot.2009.1753">Clot et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>, <xref ref-type="bibr" rid="spr-def.REF.koht.2014.7">Koht et al 2014</xref>].</p>
          <p><bold>Clinical features present in more than 65% of affected individuals</bold> include motor and speech delay, axial hypotonia, dystonia, weakness, oculogyric crises, and diurnal fluctuation of symptoms with sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, drowsiness, difficulty initiating or maintaining sleep related to alteration of the sleep-wake circadian rhythm).</p>
          <p>Most affected individuals have nonspecific features in infancy including developmental delays and axial hypotonia. In the next few years other features that may develop include limb hypertonia, hyperreflexia, dystonia, and more apparent diurnal fluctuation and sleep disturbance.</p>
          <p>In some instances, dystonia may present as paroxysmal stiffening of limbs and/or trunk with gaze deviation and tremor of the tongue, limbs, and/ or head [<xref ref-type="bibr" rid="spr-def.REF.dill.2012.e29">Dill et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>].</p>
          <p><bold>Numerous rarely reported findings</bold> overlap with those typical of other disorders of monoamine neurotransmitter biosynthesis (see <xref ref-type="sec" rid="spr-def.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <p>Seizures (mostly febrile) occasionally occur, though frequency may be over-reported as oculogyric crises and paroxysmal stiffening episodes may be confused with seizures.</p>
          <p>A few reports note low birth weight [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>], poor somatic growth [<xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>], and/or microcephaly [<xref ref-type="bibr" rid="spr-def.REF.blau.1998.433">Blau et al 1998</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>].</p>
          <p>During later childhood, abnormalities in behavior and cognition become more apparent. These may be under-reported due to the prominence of the motor features.</p>
          <p>While many affected individuals have intellectual disability, others with mild learning disabilities or normal cognition have been reported.</p>
          <p>Psychiatric and/or behavioral findings most commonly include inattention, irritability, and anxiety; however, a wide range of symptoms may occur. It is hypothesized (though not yet proven) that early treatment may mitigate cognitive or psychiatric/behavioral abnormalities.</p>
        </sec>
        <sec id="spr-def.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Although several possible genotype-phenotype correlations have been suggested in individuals with biallelic <italic toggle="yes">SPR</italic> pathogenic variants, due to the small number of affected individuals these conclusions remain uncertain [<xref ref-type="bibr" rid="spr-def.REF.arrabal.2011.183">Arrabal et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]. Phenotypic variability is broad even among family members with identical pathogenic variants.</p>
          <p>One individual heterozygous for <italic toggle="yes">SPR</italic> mutation in the 5&#x02019; untranslated region with a mild form of L-dopa responsive dystonia and reduced SR activity in fibroblasts has been reported [<xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>].</p>
        </sec>
        <sec id="spr-def.Nomenclature">
          <title>Nomenclature</title>
          <p>Two individuals originally reported as having &#x0201c;central&#x0201d; dihydropteridine reductase (DHPR) deficiency [<xref ref-type="bibr" rid="spr-def.REF.blau.1998.433">Blau et al 1998</xref>, <xref ref-type="bibr" rid="spr-def.REF.blau.1999.216">Blau et al 1999</xref>] were later diagnosed with SRD [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>].</p>
        </sec>
        <sec id="spr-def.Prevalence">
          <title>Prevalence</title>
          <p>No data are available on the prevalence of SRD.</p>
          <p>A total of approximately 50 probands have been reported to date [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>, <xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>, <xref ref-type="bibr" rid="spr-def.REF.neville.2005.2291">Neville et al 2005</xref>, <xref ref-type="bibr" rid="spr-def.REF.abeling.2006.116">Abeling et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.echenne.2006.308">Echenne et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2006.2032">Friedman et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.verbeek.2008.403">Verbeek et al 2008</xref>, <xref ref-type="bibr" rid="spr-def.REF.clot.2009.1753">Clot et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.kusmierska.2009.s5">Kusmierska et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.leusemenescu.2010.307">Leu-Semenescu et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.mazzuca.2010">Mazzuca et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.wali.2010.954">Wali et al 2010</xref>, <xref ref-type="bibr" rid="spr-def.REF.arrabal.2011.183">Arrabal et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.dill.2012.e29">Dill et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.thibert.2012.79">Thibert et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</xref>, <xref ref-type="bibr" rid="spr-def.REF.koht.2014.7">Koht et al 2014</xref>].</p>
          <p>SRD may be under-recognized due to lack of awareness.</p>
        </sec>
      </sec>
      <sec id="spr-def.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">SPR</italic>.</p>
      </sec>
      <sec id="spr-def.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
          <bold>L-dopa responsive motor disorders</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monoamine neurotransmitter disorders.</bold> Defects in the synthesis of the monoamine neurotransmitters dopamine, serotonin, epinephrine, and norepinephrine result in a heterogeneous group of disorders. Neurologic manifestations of several of these disorders may respond to treatment with L-dopa [<xref ref-type="bibr" rid="spr-def.REF.nygaard.1991.174">Nygaard et al 1991</xref>, <xref ref-type="bibr" rid="spr-def.REF.furukawa.1999.709">Furukawa &#x00026; Kish 1999</xref>] including SRD and the following:</p>
            <list list-type="bullet">
              <list-item>
                <p><related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter"><bold>DYT-GCH1/GTP cyclohydrolase 1-deficient dopa-responsive dystonia</bold></related-object> is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral levodopa. The average age of onset is approximately six years. This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms. Initial symptoms are often gait difficulties attributable to flexion-inversion (equinovarus posture) of the foot. Occasionally, initial symptoms are arm dystonia, postural tremor of the hand, or slowness of movements. Brisk deep-tendon reflexes in the legs, ankle clonus, and/or the striatal toe (dystonic extension of the big toe) are present in many affected individuals. In general, gradual progression to generalized dystonia is observed. Intellectual, cerebellar, sensory, and autonomic disturbances do not occur. Manifestations of sepiapterin reductase deficiency typically begin earlier than those in DYT-GCH1/GTP cyclohydrolase 1-deficient dopa-responsive dystonia, although individuals with mild findings of SRD may mimic this condition.</p>
              </list-item>
              <list-item>
                <p><related-object link-type="booklink" source-id="gene" document-id="thdrd" document-type="chapter"><bold>DYT-TH/tyrosine hydroxylase deficiency</bold></related-object> is associated with a broad phenotypic spectrum that mirrors that observed in SRD. Based on severity of symptoms/signs as well as responsiveness to levodopa therapy, clinical phenotypes caused by <italic toggle="yes">TH</italic> pathogenic variants are divided into (1) TH-deficient dopa-responsive dystonia (DRD: the mild form of TH deficiency [DYT5b]), (2) TH-deficient infantile parkinsonism with motor delay (the severe form), and (3) TH-deficient progressive infantile encephalopathy (the very severe form). In contrast to SRD, individuals with DYT-TH do not have abnormalities of pterin or serotonin metabolism, though clinically these distinctions are not always apparent.</p>
              </list-item>
              <list-item>
                <p><bold>Aromatic L-amino acid decarboxylase (AADC) deficiency</bold> is a disorder of biogenic amine metabolism that leads to combined deficiency of serotonin and all catecholamines. Similar to SRD, symptoms begin in infancy and are characterized by developmental delay, axial hypotonia with limb hypertonia, dystonia and parkinsonian features including bradykinesia and rigidity. Chorea and oculogyric crises may be present. Autonomic and endocrinologic abnormalities also occur. Diurnal fluctuation may be present though is generally less pronounced than in SRD. A rare subset of patients show therapeutic benefit with L-dopa [<xref ref-type="bibr" rid="spr-def.REF.chang.2004.435">Chang et al, 2004</xref>] or with other dopaminergic agents (dopamine agonists, methylphenydate, MAO inhibitors) that do not require AADC to be active.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Other.</bold> Improvement with L-dopa may also occur in juvenile Parkinson disease (see below) or may be a nonspecific feature of several motor disorders.</p>
          </list-item>
        </list>
        <p><bold>Dystonia</bold> may be a prominent, though often late and not universal feature of SRD [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]. For a detailed differential for dystonia, see <related-object link-type="booklink" source-id="gene" document-id="dystonia-ov" document-type="chapter"><underline>Dystonia Overview</underline></related-object>.</p>
        <p><bold>Cerebral palsy.</bold> Sepiapterin reductase deficiency (SRD) often presents with nonspecific symptoms including global delay with hypotonia or a nonspecific gait disorder, often with cognitive impairment. Hyperreflexia and/or striatal toe (simulating a Babinski reflex but without fanning of the toes) may be present. Oculogyric crises, if recognized, are a frequent clue to dopamine deficiency syndrome; however, as other neurologic manifestations are nonspecific, affected individuals may be misdiagnosed with cerebral palsy or an undefined L-dopa-responsive motor disorder [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]. These features as well as the varied and nonspecific presentation may lead to a misdiagnosis of cerebral palsy [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]. The differential for global delay and cerebral palsy are broad and beyond the scope of this review.</p>
        <p>A suggested algorithm for evaluation of patients with global delay with hypotonia, dystonia, or L-dopa-responsive motor disorder may be found in <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al [2012]</xref>.</p>
        <p><bold>Juvenile Parkinson disease.</bold> Parkinsonian signs are frequent and may suggest juvenile Parkinson disease, most commonly caused by mutation of <italic toggle="yes">PRKN</italic>, <italic toggle="yes">PINK1</italic>, <italic toggle="yes">DJ1</italic>, or <italic toggle="yes">ATP13A2</italic>. Typically manifestations in SRD begin at an earlier age than juvenile Parkinson disease. Differentiation between SRD and juvenile Parkinson disease is critical for prognostication and therapeutic management: Individuals with SRD may derive sustained benefit from L-dopa whereas those with juvenile Parkinson disease will develop complications with L-dopa therapy (and although it is controversial, dopamine agonists should be considered instead).</p>
        <p><bold>Disorders of biopterin metabolism.</bold> Tetrahydrobiopterin (BH<sub>4</sub>) deficiencies are caused by biallelic pathogenic variants in one of the genes involving biosynthesis or recycling of BH<sub>4</sub>, a cofactor in the phenylalanine, tyrosine, and tryptophan hydroxylation reaction. These genes and disorders are summarized in <xref ref-type="table" rid="spr-def.T.tetrahydrobiopterin_bh4_defici">Table 2</xref>.</p>
        <table-wrap id="spr-def.T.tetrahydrobiopterin_bh4_defici" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Tetrahydrobiopterin (BH<sub>4</sub>) Deficiencies</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                <th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Disorder</th>
                <th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">OMIM</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                  <italic toggle="yes">GCH1</italic>
                </td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">GTP cyclohydrolase I deficiency</td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/233910">233910</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                  <italic toggle="yes">PTS</italic>
                </td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency</td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261640">261640</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                  <italic toggle="yes">PCBD1</italic>
                </td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Pterin-4a-alpha-carbinolamine dehydratase deficiency</td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/264070">264070</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                  <italic toggle="yes">QDPR</italic>
                </td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Dihydropteridine reductase (DHPR) deficiency</td>
                <td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261630">261630</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Other.</bold> Symptoms, which result from impaired phenylalanine homeostasis and serotonin and catecholamine biosynthesis, overlap significantly with SRD. Unlike SRD, these conditions typically (though not always) present with hyperphenylalaninemia detected on newborn screening. More information on the BH<sub>4</sub> deficiencies can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">www.biopku.org</ext-link>.</p>
      </sec>
      <sec id="spr-def.Management_1">
        <title>Management</title>
        <sec id="spr-def.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with sepiapterin reductase deficiency (SRD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic consultation</p>
            </list-item>
            <list-item>
              <p>Physical therapy, occupational therapy, and speech therapy evaluations depending on severity of manifestations</p>
            </list-item>
            <list-item>
              <p>Neuropsychological evaluation depending on the severity of manifestations</p>
            </list-item>
            <list-item>
              <p>Social services consultation depending on the severity of manifestations</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="spr-def.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Therapy is aimed at correcting central nervous system (CNS) neurotransmitter deficits.</p>
          <p>Recommended treatments are based on the few reported cases in the literature and extrapolation from strategies employed in treatment of other neurotransmitter disorders.</p>
          <p>While the medications discussed below reduce manifestations of SRD, response can range from complete resolution to partial improvement. These medications most consistently correct motor abnormalities while in some cognitive manifestations remain more refractory.</p>
          <p>Often, medications must be prescribed &#x0201c;off-label&#x0201d; without established pediatric dose ranges [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>L-dopa</bold> (0.1-16 mg/kg/day) in combination with 10%-25% carbidopa (or another peripheral decarboxylase inhibitor) is the main therapy to correct CNS dopamine deficiency. Optimal therapeutic level is determined by clinical response. Note: (1) Dose-related dyskinesias may occur [<xref ref-type="bibr" rid="spr-def.REF.abeling.2006.116">Abeling et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.neville.2007.85">Neville 2007</xref>, <xref ref-type="bibr" rid="spr-def.REF.arrabal.2011.183">Arrabal et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]; they can be eliminated in most instances with reduced dosage or addition of a dopamine agonist to reduce fluctuations in dopaminergic stimulation [<xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>]. (2) Gastrointestinal side effects such as nausea may be reduced by increasing the proportion of administered carbidopa. (3) Although not reported, it is theoretically possible that individuals with SRD receiving high-dose L-dopa could develop cerebral folate deficiency and require supplementation with folinic acid (as has been observed in L-aromatic amino acid decarboxylase deficiency [<xref ref-type="bibr" rid="spr-def.REF.brun.2010.64">Brun et al 2010</xref>]).</p>
            </list-item>
            <list-item>
              <p><bold>5-hydroxytryptophan</bold> (5-HTP) (1-6mg/kg/day) also in combination with <bold>carbidopa</bold> to correct CNS serotonin deficiency has shown additional clinical benefit in some.</p>
            </list-item>
            <list-item>
              <p><bold>Tetrahydrobiopterin</bold> (BH<sub>4</sub>; sapropterin dihydrocloride) may in theory be of benefit, although none was reported in four patients treated for only a short time [<xref ref-type="bibr" rid="spr-def.REF.friedman.2006.2032">Friedman et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>]. Note that it is difficult to achieve adequate CNS levels of BH<sub>4</sub> due to limited transport across the blood brain barrier.</p>
            </list-item>
            <list-item>
              <p><bold>Other agents</bold> used when L-dopa/5HTP/carbidopa are not tolerated or sufficiently effective which have shown benefit in single or small numbers of patients include:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Monoamine oxidase inhibitors (selegeline)</p>
                </list-item>
                <list-item>
                  <p>Serotonin reuptake inhibitors (sertraline)</p>
                </list-item>
                <list-item>
                  <p>Melatonin</p>
                </list-item>
                <list-item>
                  <p>Dopamine agonists (bromocriptine, pramipexole)</p>
                </list-item>
                <list-item>
                  <p>Anticholinergics</p>
                </list-item>
                <list-item>
                  <p>Methylphenidate</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="spr-def.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>Physical, occupational, and speech therapy may improve or maintain function.</p>
        </sec>
        <sec id="spr-def.Surveillance">
          <title>Surveillance</title>
          <p>Data are insufficient to determine how frequently CSF levels of dopamine and serotonin metabolites should be evaluated and whether these levels should be used to adjust medication doses. Practices range from at least annual assessment of CNS neurotransmitter metabolites to adjustment of neurotransmitter precursor therapy based solely on clinical manifestations.</p>
          <p>Because clinical manifestations are more difficult to assess in children, it would seem prudent to evaluate CSF neurotransmitter metabolites two to four times yearly in children younger than age two years and at least yearly in children younger than age ten years.</p>
          <p>Note: Plasma prolactin levels may inversely correlate with CNS dopamine levels but are neither a sensitive nor specific marker [<xref ref-type="bibr" rid="spr-def.REF.leuzzi.2002.1241">Leuzzi et al 2002</xref>, <xref ref-type="bibr" rid="spr-def.REF.furukawa.2003.269">Furukawa et al 2003</xref>, <xref ref-type="bibr" rid="spr-def.REF.concolino.2008.s193">Concolino et al 2008</xref>].</p>
        </sec>
        <sec id="spr-def.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Although adverse events with specific agents have not been reported in persons with SRD, several should be avoided on a theoretic basis including:</p>
          <list list-type="bullet">
            <list-item>
              <p>Sulfa drugs, which impair BH<sub>4</sub> biosynthesis by inhibiting sepiapterin reductase [<xref ref-type="bibr" rid="spr-def.REF.haruki.2013.987">Haruki et al 2013</xref>]</p>
            </list-item>
            <list-item>
              <p>Methotrexate, which inhibits dihydropteridine reductase, an enzyme involved in BH<sub>4</sub> regeneration [<xref ref-type="bibr" rid="spr-def.REF.woody.1990.639">Woody &#x00026; Brewster 1990</xref>]</p>
            </list-item>
            <list-item>
              <p>Nitrous oxide, which may impair folate metabolism [<xref ref-type="bibr" rid="spr-def.REF.wyatt.1999.307">Wyatt &#x00026; Gill 1999</xref>]</p>
            </list-item>
            <list-item>
              <p>Neuroleptics and other dopamine antagonists (e.g., metoclopramide)</p>
            </list-item>
          </list>
        </sec>
        <sec id="spr-def.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>While no data on outcomes are available, it is appropriate to use molecular genetic testing for the <italic toggle="yes">SPR</italic> pathogenic variants identified in the proband and/or analysis of CSF neurotransmitter metabolites and pterins to clarify the genetic status of apparently asymptomatic older and younger sibs of an affected individual in order to identify as soon as possible those who would benefit from early initiation of treatment to correct CNS dopamine and serotonin deficiency.</p>
          <p>See <xref ref-type="sec" rid="spr-def.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="spr-def.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>No pregnancies have been reported to date in women with SRD.</p>
          <p>Based on reports that suggest that L-dopa may be advantageous during pregnancy in women with GTP cyclohydrolase 1-deficient dopa-responsive dystonia (<related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">DYT-GCH1</related-object>), it would seem prudent for women with SRD to continue L-dopa therapy during pregnancy [<xref ref-type="bibr" rid="spr-def.REF.trendergerhard.2009.839">Trender-Gerhard et al 2009</xref>, <xref ref-type="bibr" rid="spr-def.REF.watanabe.2012.559">Watanabe &#x00026; Matsubara 2012</xref>].</p>
        </sec>
        <sec id="spr-def.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="spr-def.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="spr-def.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Sepiapterin reductase deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="spr-def.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">SPR</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are generally asymptomatic and are not at risk of developing the disorder. Current data are insufficient to associate clinical manifestations with heterozygosity for an <italic toggle="yes">SPR</italic> pathogenic variant; however, several anecdotal reports have raised this possibility, including the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>An individual with a heterozygous <italic toggle="yes">SPR</italic> pathogenic variant in the 5&#x02019; untranslated region and a mild L-dopa-responsive dystonia phenotype [<xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>]</p>
                </list-item>
                <list-item>
                  <p>Fibromyalgia which segregated with carrier status in one small pedigree [<xref ref-type="bibr" rid="spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</xref>]</p>
                </list-item>
                <list-item>
                  <p>The presence of other manifestations including dystonia and parkinsonism in relatives (who had not undergone molecular genetic testing) of individuals with SRD [<xref ref-type="bibr" rid="spr-def.REF.friedman.2006.2032">Friedman et al 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.lohmann.2012.191">Lohmann et al 2012</xref>]</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier of a <italic toggle="yes">SPR</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are usually not at risk of developing the disorder (see <bold>Parents of a proband</bold>).</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Individuals with sepiapterin reductase deficiency have not been reported to reproduce; however, only a few identified individuals are of childbearing age.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">SPR</italic> pathogenic variant.</p>
        </sec>
        <sec id="spr-def.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">SPR</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="spr-def.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="spr-def.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who have or are at risk of having one or more <italic toggle="yes">SPR</italic> pathogenic variants.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="spr-def.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">SPR</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing. Because individuals with biallelic <italic toggle="yes">SPR</italic> pathogenic variants may be asymptomatic, predicting the phenotype based on results of prenatal testing may not be reliable.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">SPR</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="spr-def.Resources">
        <title>Resources</title>
      </sec>
      <sec id="spr-def.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">SPR</italic> spans 4.8 kb and comprises three exons. There is no evidence for alternative splicing variants [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="spr-def" object-id="spr-def.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> Seventeen pathogenic variants have been reported in <italic toggle="yes">SPR</italic> [<xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.koht.2014.7">Koht et al 2014</xref>]. Pathogenic variants are homozygous or compound heterozygous except for a single individual heterozygous for a <italic toggle="yes">SPR</italic> pathogenic variant in the 5&#x02019; untranslated region with a mild form of L-dopa responsive dystonia and reduced sepiapterin reductase activity in fibroblasts [<xref ref-type="bibr" rid="spr-def.REF.steinberger.2004.187">Steinberger et al 2004</xref>]. The authors did not report whether gene-targeted deletion/duplication analysis was performed to evaluate for deletion on the other allele.</p>
        <p>Known pathogenic variants are missense, nonsense, and frame-shift. Pathogenic variants have been found in all three exons, the 5&#x02019; untranslated region, and the intronic region in the splicing acceptor consensus sequence preceding exon 3 [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>, <xref ref-type="bibr" rid="spr-def.REF.koht.2014.7">Koht et al 2014</xref>].</p>
        <p>Homozygosity for the intronic variant c.596-2A&#x0003e;G was the most common genotype found in a cohort of affected individuals from Malta, suggesting a possible founder effect [<xref ref-type="bibr" rid="spr-def.REF.neville.2005.2291">Neville et al 2005</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>, <xref ref-type="bibr" rid="spr-def.REF.friedman.2012.520">Friedman et al 2012</xref>].</p>
        <table-wrap id="spr-def.T.spr_pathogenic_variants_discus" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p><italic toggle="yes">SPR</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.596-2A&#x0003e;G</td>
                <td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Abnormal splicing</td>
                <td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003124.4">NM_003124.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_003115.1">NP_003115.1</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the author.&#x000a0;<italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic>&#x000a0;follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">SPR</italic> cDNA encodes a monomer of 261 amino acids. Sepiapterin reductase is a homodimer with a predicted molecular mass of 56 kd [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Biallelic pathogenic variants in <italic toggle="yes">SPR</italic> result in dysfunctional SR protein, decreased synthesis of BH<sub>4,</sub> and accumulation of BH<sub>2</sub> and sepiapterin in the central nervous system. Alternative pathways in the liver and other tissues compensate for lack of sepiapterin reductase and account for normal phenylalanine levels and lack of neurotransmitter or pterin abnormalities in the periphery [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>].</p>
        <p>Symptoms arise primarily from impaired central nervous system serotonin and catecholamine production. Reduced neurotransmitter production is the result of both reduced activity of tyrosine and tryptophan hydroxylases due to reduced levels of BH<sub>4</sub> cofactor as well as direct inhibition of these hydroxylases by accumulated BH<sub>2</sub> [<xref ref-type="bibr" rid="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</xref>]. In addition, altered BH<sub>4</sub>:BH<sub>2</sub> ratios may uncouple nitric oxide synthase (an enzyme dependent on the BH<sub>4</sub> cofactor), and increase free radical production [<xref ref-type="bibr" rid="spr-def.REF.blau.2001.172">Blau et al 2001</xref>, <xref ref-type="bibr" rid="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</xref>]. The effect of these perturbations on the clinical picture is unclear.</p>
        <p>Neurotransmitter deficiency is primarily responsible for clinical manifestations; however, several lines of evidence suggest that sepiapterin reductase deficiency may also affect maturation of the dopaminergic system as well as stabilization of the protein tyrosine hydroxylase [<xref ref-type="bibr" rid="spr-def.REF.okuno.1985.2633">Okuno &#x00026; Fujisawa1985</xref>, <xref ref-type="bibr" rid="spr-def.REF.takazawa.2008.787">Takazawa et al 2008</xref>, <xref ref-type="bibr" rid="spr-def.REF.homma.2011.1445">Homma et al 2011</xref>, <xref ref-type="bibr" rid="spr-def.REF.homma.2013.70">Homma et al 2013</xref>].</p>
      </sec>
      <sec id="spr-def.References">
        <title>References</title>
        <sec id="spr-def.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="spr-def.Literature_Cited.reflist0">
            <ref id="spr-def.REF.abeling.2006.116">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abeling</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakker</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroomer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booij</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2006</year>
                <volume>89</volume>
                <fpage>116</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">16650784</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.arrabal.2011.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arrabal</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teresa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez-Alcudia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medrano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez-Solana</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roldan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ormazabal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Cerda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugarte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desviat</surname>
                    <given-names>LR</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlations in sepiapterin reductase deficiency. A splicing defect accounts for a new phenotypic variant.</article-title>
                <source>Neurogenetics</source>
                <year>2011</year>
                <volume>12</volume>
                <fpage>183</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">21431957</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.bainbridge.2011.87re3">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bainbridge</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiszniewski</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murdock</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzaga-Jauregui</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newsham</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fink</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gingras</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muzny</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoang</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yousaf</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lupski</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Whole-genome sequencing for optimized patient management.</article-title>
                <source>Sci Transl Med.</source>
                <year>2011</year>
                <volume>3</volume>
                <fpage>87re3</fpage>
                <pub-id pub-id-type="pmid">21677200</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.blau.2001.172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonafe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Tetrahydrobiopterin deficiencies without hyperphenylalaniemia: diagnosis and genetics of Dopa-responsive dystonia and sepiapterin reductase deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <year>2001</year>
                <volume>74</volume>
                <fpage>172</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">11592814</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.blau.1998.433">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renneberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Dihydropteridine reductase deficiency localized to the central nervous system.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>1998</year>
                <volume>21</volume>
                <fpage>433</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9700606</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.blau.1999.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renneberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penzien</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                </person-group>
                <article-title>Variant of dihydropteridine reductase deficiency without hyperphenylalaninaemia: effect of oral phenylalanine loading.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>1999</year>
                <volume>22</volume>
                <fpage>216</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">10384371</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.bonaf_.2006">
              <mixed-citation publication-type="book">Bonaf&#x000e9; L. Sepiapterin reductase deficiency. In: Blau N, ed. <italic toggle="yes">PKU and BH4 Advances in Phenylketonuria and Tetrahydrobiopterin.</italic> Heilbronn: SPS Verlagsgesellschaft. 2006:593-611.</mixed-citation>
            </ref>
            <ref id="spr-def.REF.bonaf_.2001a.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonaf&#x000e9;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leimbacher</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kierat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts.</article-title>
                <source>Clin Chem</source>
                <year>2001a</year>
                <volume>47</volume>
                <fpage>477</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">11238300</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.bonaf_.2001b.269">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonaf&#x000e9;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penzien</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czarnecki</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia.</article-title>
                <source>Am J Hum Genet</source>
                <year>2001b</year>
                <volume>69</volume>
                <fpage>269</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">11443547</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.br_utigam.2002.287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Br&#x000e4;utigam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weykamp</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Neurotransmitter metabolites in CSF: an external quality control scheme.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2002</year>
                <volume>25</volume>
                <fpage>287</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">12227459</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.brun.2010.64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brun</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngu</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keng</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ch'ng</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choy</surname>
                    <given-names>YS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbeek</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wassenberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000e9;gal</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orcesi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonduti</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Accorsi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testard</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kern</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manegold</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency.</article-title>
                <source>Neurology</source>
                <year>2010</year>
                <volume>75</volume>
                <fpage>64</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">20505134</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.chang.2004.435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPherson</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedell</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knust</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brautigam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.</article-title>
                <source>Ann Neurol</source>
                <year>2004</year>
                <volume>55</volume>
                <fpage>435</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14991824</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.clot.2009.1753">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazeneuve</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roze</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castelnau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabro</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landrieu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponsot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doummar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thobois</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutchinson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toutain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fedirko</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouteiller</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LeGuern</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidailhet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>the French Dystonia Network. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia.</article-title>
                <source>Brain.</source>
                <year>2009</year>
                <volume>132</volume>
                <fpage>1753</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">19491146</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.concolino.2008.s193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Concolino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muzzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapsomaniki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moricca</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pascale</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>2008</year>
                <volume>31</volume>
                <fpage>S193</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18425437</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.dill.2012.e29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dill</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somerville</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.</article-title>
                <source>Neurology</source>
                <year>2012</year>
                <volume>78</volume>
                <fpage>e29</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">22291068</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.echenne.2006.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Echenne</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roubertie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penzien</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy.</article-title>
                <source>Pediatr Neurol</source>
                <year>2006</year>
                <volume>35</volume>
                <fpage>308</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">17074599</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.friedman.2006.2032">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency.</article-title>
                <source>Neurology.</source>
                <year>2006</year>
                <volume>67</volume>
                <fpage>2032</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17159114</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.friedman.2012.520">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roze</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasperini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saletti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wali</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eiroa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neville</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parascandalo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zafeiriou</surname>
                    <given-names>DI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrabal-Fernandez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dill</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Echenne</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez-Solana</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kusmierska</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tijssen</surname>
                    <given-names>MAJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzuca</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penzien</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sykut-Cegielska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szymanska</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy.</article-title>
                <source>Ann Neurol</source>
                <year>2012</year>
                <volume>71</volume>
                <fpage>520</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">22522443</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.furukawa.2003.269">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furtado</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kish</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <article-title>Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation.</article-title>
                <source>Neurology</source>
                <year>2003</year>
                <volume>61</volume>
                <fpage>269</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">12874420</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.furukawa.1999.709">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kish</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <article-title>Dopa-responsive dystonia: recent advances and remaining issues to be addressed.</article-title>
                <source>Mov Disord.</source>
                <year>1999</year>
                <volume>14</volume>
                <fpage>709</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">10495030</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.haruki.2013.987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haruki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorska</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pojer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnsson</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs.</article-title>
                <source>Science</source>
                <year>2013</year>
                <volume>340</volume>
                <fpage>987</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">23704574</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.homma.2013.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Homma</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katoh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuoka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichinose</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>The role of tetrahydrobiopterin and catecholamines in the developmental regulation of tyrosine hydroxylase level in the brain.</article-title>
                <source>J Neurochem</source>
                <year>2013</year>
                <volume>126</volume>
                <fpage>70</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">23647001</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.homma.2011.1445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Homma</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumi-Ichinose</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuoka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikemoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katoh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichinose</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Partial biopterin deficiency disturbs postnatal development of the dopaminergic system in the brain.</article-title>
                <source>J Biol Chem</source>
                <year>2011</year>
                <volume>286</volume>
                <fpage>1445</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">21062748</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.hyland.1997.1290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryburg</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bebin</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunasekera</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rost-Ruffner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trugman</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test.</article-title>
                <source>Neurology</source>
                <year>1997</year>
                <volume>48</volume>
                <fpage>1290</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9153460</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.hyland.1993.10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surtees</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowron</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howells</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population.</article-title>
                <source>Pediatr Res</source>
                <year>1993</year>
                <volume>34</volume>
                <fpage>10</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">7689195</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.koht.2014.7">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koht</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rengmark</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opladen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bj&#x000f8;rnar&#x000e5;</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tallaksen</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toft</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene.</article-title>
                <source>Acta Neurol Scand Suppl.</source>
                <year>2014</year>
                <issue>198</issue>
                <fpage>7</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">24588500</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.kusmierska.2009.s5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kusmierska</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szymanska</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malunowicz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meilei</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tryfon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rokicki</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pronicka</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sykut-Cegielska</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>2009</year>
                <volume>32</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S5</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">19130291</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.leusemenescu.2010.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leu-Semenescu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnulf</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decaix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moussa</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boniol</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touitou</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidailhet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roze</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Sleep and rhythm consequences of a genetically induced loss of serotonin.</article-title>
                <source>Sleep.</source>
                <year>2010</year>
                <volume>33</volume>
                <fpage>307</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">20337188</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.leuzzi.2002.1241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardona</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artiola</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonozzi</surname>
                    <given-names>I.</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome.</article-title>
                <source>Neurology.</source>
                <year>2002</year>
                <volume>59</volume>
                <fpage>1241</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12391354</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.leuzzi.2013.2141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolve</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannini</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angeloni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Very early pattern of movement disorders in sepiapterin reductase deficiency.</article-title>
                <source>Neurology</source>
                <year>2013</year>
                <volume>81</volume>
                <fpage>2141</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">24212389</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.lohmann.2012.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lohmann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;ro&#x0011f;lu</surname>
                    <given-names>&#x000c7;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanagasi</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dursun</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tasan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolun</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood.</article-title>
                <source>Parkinsonism Relat Disord</source>
                <year>2012</year>
                <volume>18</volume>
                <fpage>191</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">22018912</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.mazzuca.2010">
              <mixed-citation publication-type="confproc">Mazzuca M, Christa L, Damaj L, Plouin P, Dauvilliers Y, Rabier D, Clot F, Odent S, Benoist JF, De Lonlay P. Dopa-responsive hypersomnia in combined sepiapterin reductase (SR) and methyl malonyl CoA epimerase (MCEE) deficiency. Istanbul, Turkey: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism; 2010.</mixed-citation>
            </ref>
            <ref id="spr-def.REF.neville.2007.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neville</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital DOPA-responsive disorders: a diagnostic and therapeutic challenge to the cerebral palsies?</article-title>
                <source>Dev Med Child Neurol.</source>
                <year>2007</year>
                <volume>49</volume>
                <fpage>85</fpage>
                <pub-id pub-id-type="pmid">17253992</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.neville.2005.2291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neville</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parascandalo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrugia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felice</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder.</article-title>
                <source>Brain.</source>
                <year>2005</year>
                <volume>128</volume>
                <fpage>2291</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16049044</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.nygaard.1991.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nygaard</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahn</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Dopa-responsive dystonia: long-term treatment response and prognosis.</article-title>
                <source>Neurology.</source>
                <year>1991</year>
                <volume>41</volume>
                <fpage>174</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">1899474</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.okuno.1985.2633">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okuno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujisawa</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>A new mechanism for regulation of tyrosine 3-monooxygenase by end product and cyclic AMP-dependent protein kinase.</article-title>
                <source>J Biol Chem</source>
                <year>1985</year>
                <volume>260</volume>
                <fpage>2633</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">2857715</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.steinberger.2004.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goriuonov</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitsch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hummel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>U.</given-names>
                  </name>
                </person-group>
                <article-title>Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia.</article-title>
                <source>Neurogenetics</source>
                <year>2004</year>
                <volume>5</volume>
                <fpage>187</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15241655</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.takazawa.2008.787">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takazawa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujimoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Homma</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumi-Ichinose</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichinose</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katoh</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>A brain-specific decrease of the tyrosine hydroxylase protein in sepiapterin reductase-null mice--as a mouse model for Parkinson's disease.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <year>2008</year>
                <volume>367</volume>
                <fpage>787</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">18201550</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.thibert.2012.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thibert</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Levodopa response reveals sepiapterin reductase deficiency in a female heterozygote with adrenoleukodystrophy.</article-title>
                <source>JIMD Rep</source>
                <year>2012</year>
                <volume>3</volume>
                <fpage>79</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">23430877</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.trendergerhard.2009.839">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trender-Gerhard</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwingenschuh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mir</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerhard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polke</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2009</year>
                <volume>80</volume>
                <fpage>839</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">19332422</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.verbeek.2008.403">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verbeek</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagerwerf</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeling</surname>
                    <given-names>NGGM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargiami</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zafeiriou</surname>
                    <given-names>DI</given-names>
                  </name>
                </person-group>
                <article-title>Two Greek siblings with sepiapterin reductase deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <year>2008</year>
                <volume>94</volume>
                <fpage>403</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18502672</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.wali.2010.954">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wali</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thony</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Sepiapterin reductase deficiency: two Indian siblings with unusual clinical features.</article-title>
                <source>Mov Disord.</source>
                <year>2010</year>
                <volume>25</volume>
                <fpage>954</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20222129</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.watanabe.2012.559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Good obstetric outcome in a patient with Segawa disease.</article-title>
                <source>Arq Neuropsiquiatr</source>
                <year>2012</year>
                <volume>70</volume>
                <fpage>559</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">22836471</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.woody.1990.639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woody</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewster</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency.</article-title>
                <source>Dev Med Child Neurol</source>
                <year>1990</year>
                <volume>32</volume>
                <fpage>639</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">2391014</pub-id>
              </element-citation>
            </ref>
            <ref id="spr-def.REF.wyatt.1999.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wyatt</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <article-title>An absolute contraindication to nitrous oxide.</article-title>
                <source>Anaesthesia</source>
                <year>1999</year>
                <volume>54</volume>
                <fpage>307</fpage>
                <pub-id pub-id-type="pmid">10364889</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="spr-def.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="spr-def.Suggested_Reading.reflist0">
            <ref id="spr-def.REF.friedman.2014">
              <mixed-citation publication-type="book">Friedman J, Opladen T. L-dopa-responsive dystonia syndromes. In: Hoffmann G, Blau N, eds. <italic toggle="yes">Congenital Neurotransmitter Disorders: A Clinical Approach.</italic> New York, NY; Nova Biomedical. 2014:17-38.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="spr-def.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="spr-def.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Thank you to patients and families whose participation has enabled us to learn about sepiapterin reductase deficiency and bring benefit to individuals identified with this condition in the future.</p>
        </sec>
        <sec id="spr-def.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>1 July 2015 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>26 January 2015 (jf) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
